Cancer immunotherapy prolongs and saves lives. Learn to incorporate it into your practice.

Are your patients receiving all of their cancer care options?

PROGRAM ORGANIZERS
Alain Algazi, MD – University of California, San Francisco
Michael Buljan, NP – University of California, San Francisco
Adil Daud, MD – University of California, San Francisco

SESSION TOPICS
- Basic Principles of Cancer Immunotherapy
- Immunotherapy for the Treatment of: Melanoma; Lung Cancer; Genitourinary Cancers; Hematologic Malignancies; Head and Neck Cancers
- Overcoming Operational and Reimbursement Barriers to Incorporating Immunotherapy Into Community Practice
- Immune-Related Adverse Event (irAE) Management in the clinic and the Emergency Room

Register Now: bit.ly/aci17sf
Discounted Early Registration Deadline: April 14, 2017
Advance Online Registration Deadline: April 28, 2017
Onsite Registration Available

For more information, including full accreditation information, and to register, visit bit.ly/aci17sf

The Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.